New Drug Combo Extends Survival in Platinum-Resistant Ovarian Cancer by 4 Months
Relacorilant plus nab-paclitaxel significantly improved overall survival compared to standard treatment in advanced ovarian cancer patients.
Summary
The ROSELLA trial tested relacorilant, a glucocorticoid receptor antagonist, combined with nab-paclitaxel in 381 patients with platinum-resistant ovarian cancer. The combination extended median overall survival by 4.1 months compared to nab-paclitaxel alone (16.0 vs 11.9 months). At 18 months, 46% of patients receiving the combination were alive versus 27% on standard treatment. The 35% reduction in death risk was statistically significant without requiring biomarker selection. Side effects were manageable and similar between groups when adjusted for treatment duration.
Detailed Summary
Platinum-resistant ovarian cancer represents one of the most challenging oncological conditions, with limited treatment options and poor survival outcomes. The ROSELLA trial offers new hope by demonstrating that adding relacorilant to standard chemotherapy can meaningfully extend life.
This international phase 3 trial randomized 381 patients with platinum-resistant ovarian cancer to receive either relacorilant plus nab-paclitaxel or nab-paclitaxel alone. Relacorilant is a selective glucocorticoid receptor antagonist that makes cancer cells more sensitive to chemotherapy. All patients had previously received bevacizumab, and 61% had received PARP inhibitors.
The results were striking: patients receiving the combination lived a median of 16.0 months compared to 11.9 months with standard treatment alone—a 4.1-month improvement. The hazard ratio for death was 0.65, representing a 35% reduction in death risk. Eighteen-month survival rates were 46% versus 27%, respectively.
Crucially, this benefit occurred without requiring biomarker selection, meaning all patients with platinum-resistant disease could potentially benefit. The safety profile was manageable, with neutropenia, anemia, fatigue, and nausea being the most common side effects.
These findings could establish relacorilant plus nab-paclitaxel as a new standard treatment for platinum-resistant ovarian cancer, addressing a significant unmet medical need in this difficult-to-treat population.
Key Findings
- Relacorilant combination extended median survival by 4.1 months (16.0 vs 11.9 months)
- 35% reduction in death risk without requiring biomarker selection
- 18-month survival improved from 27% to 46% with combination therapy
- Safety profile manageable with neutropenia and fatigue as main side effects
- Benefit seen across all platinum-resistant ovarian cancer patients
Methodology
Open-label phase 3 randomized controlled trial conducted at 117 centers across 14 countries. Patients were randomized 1:1 to receive relacorilant plus nab-paclitaxel versus nab-paclitaxel monotherapy, with overall survival as a dual primary endpoint alongside progression-free survival.
Study Limitations
Summary based on abstract only. Long-term safety data beyond 24.8 months median follow-up not available. Cost-effectiveness and quality of life impacts not reported in this analysis.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.